Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay
Authors:
Open Access
- 1 July 2017
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 155, 121-127
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo, Inc.
This publication has 27 references indexed in Scilit:
- Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2013
- Laboratory assessment of rivaroxaban: a reviewThrombosis Journal, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation testsThrombosis Research, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adultsThrombosis Research, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Coagulation AssaysCirculation, 2005